Efficacy of biological therapies in inflammatory bowel disease: Systematic review and meta-analysis

American Journal of Gastroenterology

Volumn 106, Issue 4, 2011, Pages 644-659

  Ford, Alexander C ^a,b   Sandborn, William J ^c   Khan, Khurram J ^d   Hanauer, Stephen B ^e   Talley, Nicholas J ^f   Moayyedi, Paul ^d  

^a LEEDS GENERAL INFIRMARY   (United Kingdom)

^b UNIVERSITY OF LEEDS   (United Kingdom)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d MCMASTER UNIVERSITY   (Canada)

^e UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^f UNIVERSITY OF NEWCASTLE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AMINOSALICYLIC ACID; AZATHIOPRINE; BUDESONIDE; CERTOLIZUMAB PEGOL; CORTICOSTEROID; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; NATALIZUMAB; PLACEBO; PREDNISONE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ABDOMINAL PAIN; ARTHRALGIA; BIOLOGICAL THERAPY; CROHN DISEASE; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEVER; HEADACHE; HEALING; HUMAN; INFECTION; INFUSION REACTION; INJECTION SITE REACTION; META ANALYSIS; MYALGIA; NAUSEA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RELAPSE; REMISSION; REVIEW; SYSTEMATIC REVIEW; ULCERATIVE COLITIS; VOMITING;

ANTI-INFLAMMATORY AGENTS; ANTIBODIES; ANTIBODIES, MONOCLONAL; BIOLOGICAL THERAPY; COLITIS, ULCERATIVE; CROHN DISEASE; HUMANS; INTEGRIN ALPHA4; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; REMISSION INDUCTION; RISK; SEVERITY OF ILLNESS INDEX; TREATMENT FAILURE; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; WOUND HEALING;

EID: 79953801792     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2011.73     Document Type: Review

References (62)

1. Lofus CG, Lofus Jr EV, Harmsen WS et al Update on the incidence and prevalence of Crohn's disease and ulcerative colitis in Olmsted County, Minnesota, 1940-2000. Infamm Bowel Dis 2007;13:254-61. (Pubitemid 46465905)
2. Lofus Jr EV, Silverstein MD, Sandborn WJ et al Crohn's disease in Olmsted County, Minnesota, 1940-1993: incidence, prevalence, and survival. Gastroenterology 1999;116:1161-8.
3. Kappelman MD, Rifas-Shiman SL, Kleinman K et al The prevalence and geographic distribution of Crohn's disease and ulcerative colitis in the United States. Clin Gastroenterol Hepatol 2007; 5: 1424-9. (Pubitemid 350181588)
4. Lofus Jr EV, Silverstein MD, Sandborn WJ et al Ulcerative colitis in Olm-sted County, Minnesota, 1940-1993: incidence, prevalence, and survival. Gut 2000;46:336-43.
5. Lennard-Jones JE, Longmore AJ, Newell AC et al An assessment of prednisone, salazopyrin, and topical hydrocortisone hemisuccinate used as out-patient treatment for ulcerative colitis. Gut 1960; 1: 217-22.
6. Truelove SC, Witts LJ. Cortisone in ulcerative colits: final report on a thera-peutic trial. Br Med J 1955; 2: 1041-8.
7. Summers RW, Switz DM, Sessions Jr JTet al National cooperative Crohn's disease study (ECCDS): results of drug treatment. Gastroenterology 1979;77:847-69. (Pubitemid 9242048)
8. Faubion Jr WA, Lofus Jr EV, Harmsen WS et al Te natural history of corticosteroid therapy for Infammatory bowel disease: a population-based study. Gastroenterology 2002;121:255-60.
9. Ho GT, Chiam P, Drummond H et al Te Effcacy of corticosteroid therapy in Infammatory bowel disease: analysis of a 5-year UK inception cohort. Aliment Pharmacol Ter 2006;24:319-30. (Pubitemid 43972900)
10. Munkholm P Langholz E, Davidsen M et al. Frequency of glucocorticoid resistance and dependency in Crohn ′s disease. Gut 1994;35:360-2.
11. Lichtiger S, Present DH, Kornb luth A et al Cyclosporine in severe ulcera-tive colitis refractory to steroid therapy N Engl J Med 1994;330:1841-5. (Pubitemid 24188135)
12. Braegger CP, Nicholls S, Murch SH et al. Tumour necrosis factor alpha in stool as a marker of intestinal infammation. Lancet 1992;339:89-91.
13. MacDonald TT, Hutchings P Choy MY et al Tumour necrosis factor-alpha and interferon-gamma production measured at the single cell level in normal and infamed human intestine. Clin Exp Immunol 1990;81:301-5. (Pubitemid 20242538)
14. Breese EJ, Michie CA, Nicholls SW et al Tumor necrosis factor alpha-producing cells in the intestinal mucosa of children with Infammatory bowel disease. Gastroenterology 1994;106:1455-66. (Pubitemid 24163114)
15. Murch SH, Lamkin VA, Savage MO et al Serum concentrations of tumour necrosis factor alpha in childhood chronic Infammatory bowel disease. Gut 1991;32:913-7.
16. Binion DG, West GA, Ina K et al Enhanced leukocyte binding by intestinal microvascular endothelial cells in infammatory bowel disease. Gastroenterology 1997;112:1895-907. (Pubitemid 27240776)
17. Farstad IN, Halstensen TS, Kvale D et al. Topographicdistributionofhom- ing receptors on B and T cells in human gut-associated lymphoid tissue: relation of L-selectin and integrin alpha 4 beta 7 to naive and memory phenotypes. Am J Pathol 1997;150:187-99.
18. Watkins PE, Warren BF, Stephens S et al Treatment of ulcerative colitis in the cottontop tamarin using antibody to tumour necrosis factor alpha. Gut 1997;40:628-33. (Pubitemid 27278331)
19. Hesterberg PE, Winsor-Hines D, Briskin MJ et al Rapid resolution of chronic colitis in the cotton-top tamarin with an antibody to a gut-homing integrin alpha 4 beta 7. Gastroenterology 1996; 111: 1373-80. (Pubitemid 26362264)
20. Akobeng AK, Zachos M. Tumour necrosis factor-alpha antibody for induction of remission in Crohn's disease. Cochrane Database Syst Rev 2004, CD003574.
21. Behm BW, Bickston SJ. Tumour necrosis factor-alpha antibodyfor maintenance of remission in Crohn's disease. Cochrane Database Syst Rev 2008;23:CD006893.
22. MacDonald JK, McDonald JW Natalizumab for induction of remission in Crohn ′s disease. Cochrane Database Syst Rev 2007;24:CD006097.
23. Rahimi R Nikfar S, Abdollahi M. Do antitumour necrosis factors induce response and remission in patients with refractory Crohn ′ s disease? A systematic meta-analysis of controlled clinical trials. Biomed Pharmacother 2007; 61: 75-80. (Pubitemid 46185874)
24. Shao L-M, Chen M-Y, Chen Q-Y et al. Meta-analysis: the Effcacy and safety of certolizumab pegol in Crohn ′s disease. Aliment Pharmacol Ter 2009;29:605-14.
25. Gisbert JP Gonzalez-Lama Y Mate J. Systematic review: Infiximab therapy in ulcerative colitis. Aliment Pharmacol Ter 2007;25:19-37. (Pubitemid 44902861)
26. Lawson MM, Tomas AG, Akobeng AK. Tumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2006;19:CD005112.
27. Rahimi R Nikfar S, Abdollahi M. Meta-analysis technique conf rms the effective-ness of anti-TNF-α in the management of active ulcerative colitis when adminis-tered in combination with corticosteroids. Med Sci Monit 2007;13:13-8.
28. Peyrin-Biroulet L Deltenre P de Suray N et al. Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol 2008; 6: 644-53. (Pubitemid 351783447)
29. Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions: version 5.0.2. (updated September 2009) www.cochrane-handbook. org; Accessed July 2010.
30. DerSimonian R Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-88. (Pubitemid 17189972)
31. Higgins JPT, Tompson SG, Deeks JJ et al Measuring inconsistency in meta-analyses. Br Med J 2003; 327: 557-60. (Pubitemid 37088507)
32. Tegger M, Davey-Smith G, Schneider M et al Bias in meta-analysis detected by a simple, graphical test. Br Med J 1997; 315: 629-34. (Pubitemid 27387172)
33. Hibi T, Watanabe M, Camez A et al. Effcacy and safety of adalimumab for the treatment of Japanese patients with moderately to severely active Crohn's disease: results from a randomized controlled trial. Am J Gastroenterol 2008;103 (Suppl 1s): S414-5.
34. Targan SR, Hanauer SB, van Deventer SJH et al A short-term study of chimeric monoclonal antibody cA2 to tumour necrosis factor α for Crohn's disease. N Engl J Med 1997;337:1029-35.
35. Targan SR, Feagan BG, Fedorak RN et al Natalizumab for the treatment of active Crohn's disease: results of the ENCORE trial. Gastroenterology 2007;132:1672-83. (Pubitemid 46695722)
36. Sands BE, Kozarek R Spainhour J et al Safety and tolerability of concurrent natalizumab treatment for patients with Crohn ′ s disease not in remission while receiving infiximab. Infamm Bowel Dis 2007;13:2-11. (Pubitemid 46080003)
37. Sandborn WJ, Feagan BG, Stoinov S et al Certolizumab pegol for the treat-ment of Crohn ′s disease. N Engl J Med 2007;357:228-38. (Pubitemid 47080387)
38. Sandborn WJ, Rutgeerts P Enns R et al Adalimumab induction therapy for Crohn disease previously treated with Infiximab: a randomized trial. Ann Intern Med 2007;146:829-38. (Pubitemid 351650483)
39. Lemann M, Mary J-Y, Duclos B et al Infiximab plus azathioprine for ster-oid-dependent Crohn's disease patients: a randomized placebo-controlled trial. Gastroenterology 2006; 130: 1054-61.
40. Hanauer SB, Sandborn WJ, Rutgeerts P et al Human antitumour necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLAS-SIC-I trial. Gastroenterology 2006; 130: 323-33.
41. Schreiber S, Rutgeerts P Fedorak RN et al. A randomized, placebo-control-led trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology 2005;129:807-18. (Pubitemid 41242673)
42. Sandborn WJ, Colombel J-F, Enns R et al Natalizumab induction and maintenance therapy for Crohn ′s disease. N Engl J Med 2005;353:1912-25. (Pubitemid 41565956)
43. Winter TA, Wright J, Ghosh S et al Intravenous CDP870, a pegylated Fab fragment of a humanized antitumour necrosis factor antibody in patients with moderate-to-severe Crohn ′ s disease: an exploratory study Aliment Pharmacol Ter 2004;20:1337-46. (Pubitemid 40040081)
44. Ghosh S, Goldin E, Gordon FH et al Natalizumab for active Crohn ′s disease. N Engl J Med 2003;348:24-32.
45. Gordon FH, Lai CWY, Hamilton MI et al A randomized placebo-control-led trial of a humanized monoclonal antibody to α 4 integrin in active Crohn's disease. Gastroenterology 2001;121:268-74. (Pubitemid 32729374)
46. Rutgeerts P D′ Haens G, Targan S et al Effcacy and safety of retreatment with anti-tumor necrosis factor antibody (Infiximab) to maintain remis-sion in Crohn ′s disease. Gastroenterology 1999;117:761-9. (Pubitemid 29468216)
47. Hanauer SB, Feagan BG, Lichtenstein GRet al. Maintenance Infiximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002;359:1541-9. (Pubitemid 34621118)
48. Colombel J-F, Sandborn WJ, Rutgeerts P et al Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007; 132: 52-65. (Pubitemid 46108762)
49. Sandborn WJ, Hanauer SB, Rutgeerts P et al. Adalimumab for maintenance treat-ment of Crohn ′ s disease: results of the CLASSIC II trial. Gut 2007; 56: 1232-9. (Pubitemid 47300424)
50. Schreiber S, Khaliq-Kareemi M, Lawrance IC et al. Maintenance therapy with certolizumab pegol for Crohn ′ s disease. N Engl J Med 2007; 357: 239-50. (Pubitemid 47080388)
51. Present DH, Rutgeerts P Targan S et al Infiximab for the treatment of f stulas in patients with Crohn ′s disease. N Engl J Med 1999;340:1398-405. (Pubitemid 29205403)
52. Colombel J-F, Schwartz DA, Sandborn WJ et al Adalimumab for the treat-ment of f stulas in patients with Crohn ′s disease. Gut 2009;58:940-8.
53. Sands BE, Anderson FH, Bernstein CN et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004;350:876-85. (Pubitemid 38252535)
54. Sandborn W Schreiber S, Feagan B et al Induction therapy with certolizu-mab pegol in patients with moderate to severe Crohn ′ s disease: a placebo-controlled trial. Am J Gastroenterol 2010;105 (Suppl 1s): S419.
55. Colombel J-F, Sandborn WJ, Reinisch W et al Infiximab, azathioprine, or combination therapy for Crohn ′s disease. N Engl J Med 2010;362: 1383-95.
56. Sands BE, Tremaine WJ, Sandborn WJ et al Infiximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study Infamm Bowel Dis 2001;7:83-8.
57. Probert CJ, Hearing SD, Schreiber S et al Infiximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial. Gut 2003;52:998-1002. (Pubitemid 36765292)
58. Jarnerot G, Hertervig E, Friis-L iby I et al Infiximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-con-trolled study Gastroenterology 2005;128:1805-11. (Pubitemid 40824691)
59. Rutgeerts P Sandborn WJ, Feagan BG et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353: 2462-76. (Pubitemid 41770166)
60. Lichtenstein GR, Feagan BG, Cohen RD et al Serious infections and mor-tality in association with therapies for Crohn's disease: TREAT registry Clin Gastroenterol Hepatol 2006;4:621-30.
61. Feagan BG, McDonald JW, Panaccione R et al A randomized trial of methotrexate in combination with Infiximab for the treatment of Crohn's disease. Gastroenterology 2008;135:294-5.
62. D'Haens G, Baert F, van Assche G et al Early combined immunosuppres-sion or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 2008;371:660-7. (Pubitemid 351284485)